Outcome in two groups of patients with allograft-prosthetic reconstruction of pelvic tumor defects.
To predict the outcomes obtained with allograft-implant composite reconstruction of pelvic defects after bone tumor resection better, a retrospective review of a prospectively collected database was done and two groups of patients were identified. These groups were compared with respect to oncologic and functional outcomes in this investigation. Group 1 included 21 patients with allograft total hip replacement reconstruction for pelvic bone tumors that required Type I and II or Type I, II, and III pelvic resections. Group 2 included five patients who required an acetabular allograft in combination with proximal femoral replacement for reconstruction of Type II pelvic resections done to treat proximal femoral bone sarcomas that invaded or surrounded the hip joint. Functional assessment was measured with three instruments (Toronto Extremity Salvage Score, Musculoskeletal Tumor Society 1987, and the Musculoskeletal Tumor Society 1993 scores). In Group 1, nine of 19 evaluable patients (two patients died in the immediate postoperative period) either retained the allograft until their death or were still alive at last followup with their allograft in place. An additional patient had revision surgery to an allograft-saddle composite that remains intact. The functional results in Group 1 were influenced heavily by the occurrence of deep infection. Nine of 19 evaluable patients developed infection, with seven patients requiring either removal of the graft (three patients) or hindquarter amputation (four patients). Two patients retained their infected allografts with long-term antibiotic suppression. In 10 Group 1 patients who did not develop infection, reasonable functional results were obtained. Group 2 patients had no infections and better functional results.


METHODS
Therapeutic study, Level IV-1 (case series). See the Guidelines for Authors for a complete description of levels of evidence.
Beadel
Gordon P
GP
University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Ontario, Canada.
McLaughlin
Catherine E
CE
Wunder
Jay S
JS
Griffin
Anthony M
AM
Ferguson
Peter C
PC
Bell
Robert S
RS
D000293:Adolescent; D000328:Adult; D016025:Bone Transplantation; D019317:Evidence-Based Medicine; D005260:Female; D005266:Femoral Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012516:Osteosarcoma / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D011183:Postoperative Complications; D019919:Prosthesis Implantation; D019651:Plastic Surgery Procedures / Q000379:methods*; D012189:Retrospective Studies; D015996:Survival Rate; D014184:Transplantation, Homologous; D016896:Treatment Outcome